Navigation Links
MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009
Date:4/27/2009

VALENCIA, Calif., April 27 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2009 first quarter financial results on Monday, May 4, 2009.

Management of the Company will host a conference call to discuss the first quarter financial results and other Company developments at 4:00 PM EDT on May 4, 2009. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (888) 566-0513 or (203) 369-3063. A replay will also be available on MannKind's website for fourteen days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFRESA(R), an ultra rapid-acting insulin and MKC253, an inhaled formulation of human GLP-1. MannKind also has two cancer immunotherapeutic products in clinical development. MannKind maintains a website at http://www.mannkindcorp.com to which the company regularly posts copies of
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MannKind Submits NDA for AFRESA for Treatment of Diabetes
2. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
3. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
4. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
5. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
6. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
7. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
8. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
9. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
10. MannKind to Present at the UBS Global Life Sciences Conference
11. MannKind Corporation Reports Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... TRIANGLE PARK, N.C. and ... agricultural research firm AgBiome, and Genective, key developer ... to accelerate the discovery of new generations of ... traits for insect control to counter the realities ... partner with Genective, aligning AgBiome,s unique insect control ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus ... the development of groundbreaking drugs to treat neurodegenerative ... today that Robert G. Miller , M.D., Director ... Sutter Health,s California Pacific Medical Center in San Francisco, ... Association for $1.5 million to help fund a ...
(Date:7/1/2015)... 2015 InferMed , ... will augment ... clinical s olutions suite   Elsevier ... products and services, announced today the acquisition of  InferMed , ... technology company. InferMed,s Arezzo technology supports clinicians in ...
(Date:6/30/2015)... Japan , July 1, 2015 R-Japan Co.,Ltd. ... on the Safety of Regenerative Medicine from the Ministry of ... on June 29, 2015. The fact that ... processing facility through the auditing from Pharmaceuticals and Medical Devices ... the application, allows it to provide stem cell manufacturing service ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2
... , PALO ALTO, Calif., Aug. 17, 2009 ... with a focus on the NS4B Hepatitis C Virus (HCV) ... Board of Directors. , , Truex is ... private pharmaceutical company focused on the development of anti-inflammatory products ...
... , SAN DIEGO, Aug. 17 Imagenetix, ... natural-based, proprietary products announced that last week Dr. Robert Hesslink, ... on his Bloomberg Radio program, Taking Stock. Dr. Hesslink ... its flagship product, InflameAway Celadrin(R), and 1-TDC, Imagenetix,s early stage ...
... Inc. (NASDAQ: VSGN ; TSX:VAS), today announced that ... Department of The NASDAQ Stock Market indicating that Vasogen ... We plan to request a hearing before the NASDAQ ... determination of the continued listing of our common stock. ...
Cached Biology Technology:Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors 2Imagenetix, Inc. Announces Interview With Bloomberg Radio 2Vasogen Receives NASDAQ Notification Related to Minimum Bid Price 2
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/24/2015)... , June 24, 2015 The biologics safety ... major drivers for the market include growth of the ... new drug launches. Over the years, the number of ... 2001 and 2010, the FDA approved 225 drug applications ... WIPO, Europe accounted for 3,822 ...
(Date:6/23/2015)... , June 23, 2015   MedNet Solutions ... supports the entire spectrum of clinical research, is ... ™ , the company,s intuitive, flexible and ... a Silver 2015 Stevie® Award by the ... & Services Website category.  The American Business Awards ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... CORVALLIS, Ore. A laboratory study has shown for the ... are linked to a side-effect of some statin drugs - ... of the most widely prescribed drugs in the world, able ... of heart attacks or other cardiovascular events. However, their role ...
... dozen Ludwig scientists from around the world presented the ... this week,s American Association for Cancer Research (AACR) Annual ... program with important diagnostic and treatment implications for emerging ... available to help patients with melanoma, researchers are developing ...
... age at which a child with autism is diagnosed ... he or she exhibits, new research from the University ... poor nonverbal communication and repetitive behaviors, were associated with ... a study in the April issue of the ...
Cached Biology News:Co-Q10 deficiency may relate to concern with statin drugs, higher risk of diabetes 2Ludwig presents advancements in immunotherapy and epigenetics at the American Association for Cancer Research Annual Meeting 2In autism, age at diagnosis depends on specific symptoms 2
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... Analysis Note: Protein determined by ... 3.2 M (NH 4 ) ... 7.0 Preparation Note: Affinity purified ... suspension • Additives: MgCl 2 ...
... miRNA Bioarray Essentials Kit provides all the necessary ... of the mir Vana miRNA Bioarrays when ... using Ambions mir Vana miRNA Labeling Kit. ... (Bioarray ID BA10001) that should be spiked into ...
... IT siRNA Tracker Intracellular Localization Kit ... straight forward approach to directly label ... in an efficient yet non-destructive manner, ... localization and functional inhibition of target ...
Biology Products: